In addition to monotherapy efficacy, combination of CD137 agonistic antibody and PD-1/PD-L1 blocking antibodies can synergistically enhance anti-tumor effects, reduce Treg cell infiltration, and prolong survival [27–31]. Here, TNFRSF9 is linked to neoplasm.